ERBB2 and breast cancer: In high-risk HR-positive, HER2-negative BC patients with no evidence of recurrence five years after diagnosis, the serial blood analysis by patient-specific RaDaR assays identified all patients with distant metastatic recurrences (7.2%) with a median ctDNA lead time of 12.4 months.